Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 12
2003 5
2004 7
2005 10
2006 14
2007 12
2008 8
2009 14
2010 16
2011 14
2012 16
2013 13
2014 5
2015 12
2016 10
2017 13
2018 15
2019 22
2020 12
2021 20
2022 22
2023 20
2024 23
2025 25
2026 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

334 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Şendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S; DESTINY-Breast09 Trial Investigators. Tolaney SM, et al. N Engl J Med. 2026 Feb 5;394(6):551-562. doi: 10.1056/NEJMoa2508668. Epub 2025 Oct 29. N Engl J Med. 2026. PMID: 41160818 Clinical Trial.
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Lévy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Bardia A, et al. N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282896 Clinical Trial.
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. Bidard FC, et al. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056/NEJMoa2502929. Epub 2025 Jun 1. N Engl J Med. 2025. PMID: 40454637 Free article. Clinical Trial.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: ishiguro h. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
Turner NC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Brufsky AM, Fasching PA, Nowecki Z, Pascual J, Karadurmus N, Gal-Yam E, Chung WP, Im SA, Zambelli A, Dalenc F, Oliveira M, Ishiguro H, Huang CS, Klinowska T, Fox S, Morrow C, Robert L, Huang-Bartlett C, Bidard FC. Turner NC, et al. Among authors: ishiguro h. Lancet Oncol. 2026 Aug;27(8):941-958. doi: 10.1016/S1470-2045(26)00287-1. Epub 2026 Jul 13. Lancet Oncol. 2026. PMID: 42442380
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey.
Takada M, Saji S, Ueno T, Masuda N, Ishiguro H, Ishida T, Saeki T, Imoto S, Ohno S, Iwata H, Sugie T, Aogi K, Takayama S, Sato N, Kai Y, Kitada M, Nakamura R, Watanabe K, Matsuyama Y, Toi M. Takada M, et al. Among authors: ishiguro h. NPJ Breast Cancer. 2025 Oct 24;11(1):113. doi: 10.1038/s41523-025-00832-w. NPJ Breast Cancer. 2025. PMID: 41136408 Free PMC article.
Tppp3 determines basal body positioning and identity of respiratory cilia via microtubule assembly and sphingolipid homeostasis.
Sakai T, Kawakita M, Seki A, Takaoka K, Kurata M, Torikai J, Atsumi S, Yawata K, Noi K, Fukutani Y, Noguchi K, Kiyokawa H, Morimoto M, Takeuchi E, Minegishi K, Aoki Y, Fujimura S, Nishizaka T, Inoue T, Nagaoka K, Tsugawa H, Hayashi H, Ishiguro H, Kozono T, Ohsawa I, Fujita Y, Matsunami H, Hamada H, Shinohara K. Sakai T, et al. Among authors: ishiguro h. Proc Natl Acad Sci U S A. 2025 Dec 9;122(49):e2503931122. doi: 10.1073/pnas.2503931122. Epub 2025 Dec 1. Proc Natl Acad Sci U S A. 2025. PMID: 41325527 Free PMC article.
Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study.
Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Yamanaka T, Aogi K, Matsumoto K, Iwasa T, Tokiwa M, Tsuneizumi M, Miyoshi Y, Kitagawa C, Yamamoto M, Takano Y, Imamura CK, Chiba Y, Takiguchi D, Ezumi T, Takano T. Sakai H, et al. Among authors: ishiguro h. Future Oncol. 2025 Nov;21(27):3459-3475. doi: 10.1080/14796694.2025.2566329. Epub 2025 Oct 24. Future Oncol. 2025. PMID: 41132084 Free PMC article.
Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan.
Fujimoto A, Ichinose Y, Matsuura K, Mikami E, Inohana W, Kurosawa T, Nakame A, Sakakibara A, Nukui A, Asano A, Shimada H, Yokogawa H, Ohara M, Ishiguro H, Hasebe T, Osaki A, Saeki T. Fujimoto A, et al. Among authors: ishiguro h. BMC Cancer. 2026 Jul 13;26(1):1201. doi: 10.1186/s12885-026-16548-4. BMC Cancer. 2026. PMID: 42437898 Free PMC article.
334 results